Literature DB >> 32424096

Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders.

Yao-Cheng Li1, Nikki K Lytle1, Seth T Gammon2, Luke Wang1, Tikvah K Hayes3, Margie N Sutton4, Robert C Bast4, Channing J Der3, David Piwnica-Worms2, Frank McCormick5, Geoffrey M Wahl6.   

Abstract

HRAS, NRAS, and KRAS4A/KRAS4B comprise the RAS family of small GTPases that regulate signaling pathways controlling cell proliferation, differentiation, and survival. RAS pathway abnormalities cause developmental disorders and cancers. We found that KRAS4B colocalizes on the cell membrane with other RAS isoforms and a subset of prenylated small GTPase family members using a live-cell quantitative split luciferase complementation assay. RAS protein coclustering is mainly mediated by membrane association-facilitated interactions (MAFIs). Using the RAS-RBD (CRAF RAS binding domain) interaction as a model system, we showed that MAFI alone is not sufficient to induce RBD-mediated RAS inhibition. Surprisingly, we discovered that high-affinity membrane-targeted RAS binding proteins inhibit RAS activity and deplete RAS proteins through an autophagosome-lysosome-mediated degradation pathway. Our results provide a mechanism for regulating RAS activity and protein levels, a more detailed understanding of which should lead to therapeutic strategies for inhibiting and depleting oncogenic RAS proteins.

Entities:  

Keywords:  HRAS; KRAS; NRAS; protein–protein interaction; split-luciferase complementation

Mesh:

Substances:

Year:  2020        PMID: 32424096      PMCID: PMC7275768          DOI: 10.1073/pnas.2000848117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

Review 1.  Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

Authors:  Adrienne D Cox; Channing J Der; Mark R Philips
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

2.  A single amino acid change in Raf-1 inhibits Ras binding and alters Raf-1 function.

Authors:  J R Fabian; A B Vojtek; J A Cooper; D K Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

3.  Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7.

Authors:  R Bremner; A Balmain
Journal:  Cell       Date:  1990-05-04       Impact factor: 41.582

4.  A versatile platform to analyze low-affinity and transient protein-protein interactions in living cells in real time.

Authors:  Yao-Cheng Li; Luo Wei Rodewald; Christian Hoppmann; Ee Tsin Wong; Sylvain Lebreton; Pavel Safar; Marcel Patek; Lei Wang; Kenneth F Wertman; Geoffrey M Wahl
Journal:  Cell Rep       Date:  2014-11-20       Impact factor: 9.423

5.  A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.

Authors:  Monique J Kauke; Alison W Tisdale; Ryan L Kelly; Christian J Braun; Michael T Hemann; K Dane Wittrup
Journal:  Mol Cancer Ther       Date:  2018-05-02       Impact factor: 6.261

6.  Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals.

Authors:  Kathryn E Luker; Matthew C P Smith; Gary D Luker; Seth T Gammon; Helen Piwnica-Worms; David Piwnica-Worms
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-29       Impact factor: 11.205

7.  Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II.

Authors:  Benjamin Stieglitz; Christine Bee; Daniel Schwarz; Ozkan Yildiz; Anna Moshnikova; Andrei Khokhlatchev; Christian Herrmann
Journal:  EMBO J       Date:  2008-07-03       Impact factor: 11.598

8.  Two distinct Raf domains mediate interaction with Ras.

Authors:  T R Brtva; J K Drugan; S Ghosh; R S Terrell; S Campbell-Burk; R M Bell; C J Der
Journal:  J Biol Chem       Date:  1995-04-28       Impact factor: 5.157

9.  A dimerization-dependent mechanism drives RAF catalytic activation.

Authors:  Thanashan Rajakulendran; Malha Sahmi; Martin Lefrançois; Frank Sicheri; Marc Therrien
Journal:  Nature       Date:  2009-09-02       Impact factor: 49.962

10.  Differential localization of Rho GTPases in live cells: regulation by hypervariable regions and RhoGDI binding.

Authors:  D Michaelson; J Silletti; G Murphy; P D'Eustachio; M Rush; M R Philips
Journal:  J Cell Biol       Date:  2001-01-08       Impact factor: 10.539

View more
  5 in total

1.  Equilibria between conformational states of the Ras oncogene protein revealed by high pressure crystallography.

Authors:  Eric Girard; Pedro Lopes; Michael Spoerner; Anne-Claire Dhaussy; Thierry Prangé; Hans Robert Kalbitzer; Nathalie Colloc'h
Journal:  Chem Sci       Date:  2022-01-13       Impact factor: 9.825

Review 2.  Development of In Vitro and In Vivo Evaluation Systems for Vitamin D Derivatives and Their Application to Drug Discovery.

Authors:  Kaori Yasuda; Miyu Nishikawa; Hiroki Mano; Masashi Takano; Atsushi Kittaka; Shinichi Ikushiro; Toshiyuki Sakaki
Journal:  Int J Mol Sci       Date:  2021-10-31       Impact factor: 5.923

3.  Protease-controlled secretion and display of intercellular signals.

Authors:  Alexander E Vlahos; Jeewoo Kang; Carlos A Aldrete; Ronghui Zhu; Lucy S Chong; Michael B Elowitz; Xiaojing J Gao
Journal:  Nat Commun       Date:  2022-02-17       Impact factor: 17.694

4.  KRAS is vulnerable to reversible switch-II pocket engagement in cells.

Authors:  James D Vasta; D Matthew Peacock; Qinheng Zheng; Joel A Walker; Ziyang Zhang; Chad A Zimprich; Morgan R Thomas; Michael T Beck; Brock F Binkowski; Cesear R Corona; Matthew B Robers; Kevan M Shokat
Journal:  Nat Chem Biol       Date:  2022-03-21       Impact factor: 16.174

Review 5.  RAS Nanoclusters: Dynamic Signaling Platforms Amenable to Therapeutic Intervention.

Authors:  Que N Van; Priyanka Prakash; Rebika Shrestha; Trent E Balius; Thomas J Turbyville; Andrew G Stephen
Journal:  Biomolecules       Date:  2021-03-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.